NovaBay Pharmaceuticals exhibits a deteriorating financial profile characterized by a 78.7% year-over-year revenue decline as of 2025Q3 and persistent operational losses. The company's reliance on external financing to cover ongoing deficits, coupled with an a...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Benchmark NBY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for NovaBay Pharmaceuticals, Inc. (NBY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.47 | $8.84M | -0.58 | -6.45% | -73.85% | -453.56% | — | |
| $2.07 | $16.77M | -0.96 | 1.84% | -60.17% | -148.91% | — | |
| $0.02 | $221.46K | -0.01 | -35.82% | -717.43% | -1358.66% | — | |
| $0.50 | $2.26M | -0.11 | — | — | -144.23% | — | |
| $0.53 | $5.94M | -0.16 | — | -651.27% | -58.58% | — | |
| $10.90 | $262.66M | 20.19 | -9.25% | 43.66% | 9.98% | — |
NovaBay Pharmaceuticals, Inc. (NBY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NBY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NovaBay Pharmaceuticals, Inc. (NBY) stock FAQ — growth, dividends, profitability & financials explained
NovaBay Pharmaceuticals, Inc. (NBY) reported $2.8M in revenue for fiscal year 2024.
NovaBay Pharmaceuticals, Inc. (NBY) saw revenue decline by 6.4% over the past year.
Yes, NovaBay Pharmaceuticals, Inc. (NBY) is profitable, generating $3.2M in net income for fiscal year 2024 (-73.8% net margin).
NovaBay Pharmaceuticals, Inc. (NBY) has a return on equity (ROE) of -453.6%. Negative ROE indicates the company is unprofitable.
NovaBay Pharmaceuticals, Inc. (NBY) had negative free cash flow of $7.0M in fiscal year 2024, likely due to heavy capital investments.
